8-K: Quoin Pharmaceuticals Announces 1-for-35 Reverse Stock Split to Maintain Nasdaq Listing

Quoin Pharmaceuticals implements a 1-for-35 reverse stock split of its American Depositary Shares (ADSs) to meet Nasdaq's minimum bid price requirement.

Summary

• Quoin Pharmaceuticals announced on April 4, 2025, that its Board of Directors approved a change in the ratio of American Depositary Shares (ADSs) to ordinary shares.
• The ratio will change from one ADS representing one ordinary share to one ADS representing thirty-five ordinary shares.
• This Ratio Change will result in a one for 35 reverse split of the issued and outstanding ADSs.
• The ordinary shares of the company will not be affected by this adjustment.
• The ADSs will continue to trade on The Nasdaq Capital Market under the symbol QNRX.
• The new CUSIP number for the ADS following the Ratio Change will be 74907L409.
• The Ratio Change will be effective at the opening of the market on April 9, 2025.
• Holders of uncertificated ADSs in DRS and DTC do not need to take any action, as the exchange will occur automatically.
• Registered holders of certificated ADSs will need to surrender their certificates to the depositary bank to receive the new ADSs.
• The objective of the Ratio Change is to increase the per share market price of the company's ADSs to comply with Nasdaq's $1.00 minimum bid price per share requirement.

Sentiment

Score: 3

Explanation: The announcement of a reverse stock split is generally viewed negatively by investors, indicating potential financial difficulties and a need to artificially inflate the stock price to maintain listing requirements.

Positives

• The company is taking action to maintain its listing on The Nasdaq Capital Market.

Negatives

• The company's ADS price is currently below Nasdaq's minimum bid price requirement, necessitating the reverse stock split.
• There is no guarantee that the reverse stock split will result in the company satisfying and maintaining the minimum bid price requirement of Nasdaq.

Risks

• The company may not be able to maintain the minimum bid price requirement of Nasdaq even after the reverse stock split.
• Failure to maintain the Nasdaq listing could have a negative impact on the company's stock price and ability to raise capital.

Future Outlook

The company hopes that the reverse stock split will allow it to maintain its Nasdaq listing, but there is no guarantee.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices. This action is often viewed negatively by investors as it can indicate financial distress or a lack of confidence in future growth.

Comparison to Industry Standards

• Many small-cap pharmaceutical companies have faced similar situations with Nasdaq compliance.
• Companies like BioPharmX and Diffusion Pharmaceuticals have also implemented reverse stock splits to maintain their listings.
• The success of these reverse splits in maintaining compliance varies, and often depends on the company's underlying financial performance and future prospects.

Stakeholder Impact

• Shareholders will see a reduction in the number of ADSs they hold, but the value of their holdings should remain approximately the same immediately following the reverse split.
• The reverse split could impact investor confidence and potentially affect the company's ability to raise capital in the future.

Next Steps

• The reverse stock split will be implemented on April 9, 2025.
• The company will need to ensure that its ADS price remains above $1.00 to maintain its Nasdaq listing.

Key Dates

Keywords

reverse stock split, ADS, American Depositary Shares, Nasdaq, minimum bid price, QNRX, Quoin Pharmaceuticals, compliance